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 26 
ABSTRACT 27 
Activation of immunologic pathways and disturbances of the extracellular matrix (ECM) 28 
dynamics are important contributors to the pathogenesis of chronic kidney diseases. Glomerular 29 
mesangial cells (MCs) are critical for homeostasis of glomerular ECM dynamics. Interleukin-6 (IL6) can 30 
act as a pro/anti- inflammatory agent relative to cell types and conditions.  This study investigated if IL6 31 
influenced ECM protein production by MCs and the regulatory pathways involved. Experiments were 32 
carried out in cultured human MCs (HMCs) and in mice. We found that overexpressing IL6 and its 33 
receptor decreased the abundance of fibronectin and collagen IV in MCs. Enzyme-linked 34 
immunosorbent assay and immunoblot analysis demonstrated that thapsigargin (an activator of store-35 
operated Ca2+ entry, SOCE), but not endoplasmic reticular stress inducer tunicamycin, significantly 36 
increased IL6 content. This thapsigargin effect was abolished by GSK-7975A, a selective inhibitor of 37 
SOCE, and by silencing Orai1 (the channel protein mediating SOCE). Furthermore, inhibition of NFκB 38 
pharmacologically and genetically significantly reduced SOCE-induced IL6 production. Thapsigargin 39 
also stimulated the nuclear translocation of p65 subunit of NFκB.  Moreover, MCs overexpressing IL6 40 
and its receptor in HMCs increased the content of the receptor for glucagon-like peptide-1 (GLP-1R), 41 
and IL6 inhibition of fibronectin was attenuated by the GLP-1R antagonist, exendin 9-39. In agreement 42 
with the HMC data, specific knockdown of Orai1 in MCs using the targeted nanoparticle delivery 43 
system in mice significantly reduced glomerular GLP-1R level. Taken together, our results suggest a 44 
novel SOCE/NFкB/IL6/GLP-1R signaling pathway which inhibits ECM protein production by MCs. 45 
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INTRODUCTION 51 
Chronic Kidney disease (CKD), also termed as ‘disease multiplier’ not only leads to end stage 52 
renal failure but also increases the mortality due to other causes like cardiovascular events (13, 27, 54). 53 
CKD including diabetic nephropathy (DN) often involves the disturbances in the extracellular matrix 54 
(ECM) protein dynamics in early stages, which eventually progress to increased production of fibrotic 55 
proteins leading to end stage renal disease (38, 44, 55).  ECM dynamics are very complex and 56 
influenced by a variety of biological and pathological factors (19, 42). Thus, understanding the 57 
molecular pathways regulating the ECM dynamics in physiological and pathological conditions is 58 
important to develop new therapeutic strategies for CKD, the current ones not being very effective (2).  59 
Glomerular mesangial cells (MCs) play a major role in glomerular ECM formation, and the 60 
production of ECM proteins by MCs is exaggerated in CKDs (1, 44, 52, 55). Inflammation and 61 
activation of the immune system are critical to CKD pathogenesis and progression (41, 62). In response 62 
to pathological stimuli, renal cells produced cytokines/chemokines that recruit the circulating immune 63 
cells, further accentuating expression of various cytokines (17, 28). Interleukin-6 (IL6) is known as a 64 
pleotropic cytokine that can act as an anti or pro-inflammatory agent depending on cell types, receptors 65 
activated, the downstream signaling pathways and the stimuli. (7, 33, 43, 46). IL6 is associated with 66 
pathophysiology of CKDs, including DN. However the exact role of IL6 in different type of kidney cells 67 
and the regulatory pathways involved are not yet defined, particularly in MCs, the major source of 68 
cytokine/chemokine in many inflammatory kidney diseases (60). The present study was aimed to 69 
investigate if IL6 modulated ECM protein production by MCs, and to define the upstream and 70 
downstream regulatory mechanisms involved. 71 
  72 
Downloaded from journals.physiology.org/journal/ajprenal at California Inst of Tech (131.215.251.179) on May 18, 2020.
5 
 
MATERIAL AND METHODS 73 
Materials: 74 
Expression plasmids: The expression plasmid for human IL6/sIL6R (pCDM8-H-IL-6) that 75 
overexpresses the protein of human IL6 fused to the human soluble IL6 receptor was obtained from Dr 76 
Stefan Rose-John, Department of Biochemistry, Christian-Albrechts-University, Kiel, Germany. 77 
siRNAs: Small interfering (si) RNA against human Orai1, (Gene Accession number :NM_032790, 78 
Sense stand sequence: 5’-UGGAACUGUCGGUCAGUCUUAUGGC-3,’) and Cy3–labeled siRNA 79 
against mouse Orai1 (Gene Accession number: NM_175423, Sense stand sequence: 5’-/5Cy3/ 80 
GGGUUGCUCAUCGUCUUUAGUGC-3’) were purchased from Integrated DNA Technologies, Inc. 81 
(Chicago, IL). Scrambled control siRNA (ON-TARGET plus non-targeting control siRNA#1; catalog #: 82 
D-001810-01-20, target sequence: UGGUUUACAUGUCGACUAA) was purchased from GE 83 
Healthcare Dharmacon (Lafayette, CO). NFκB p65 siRNA against human p65 was purchased from Cell 84 
Signaling Technology, Danvers, MA. (catalog #: 6261). 85 
Antibodies: Anti-IL6 antibody was purchased from Proteintech (catalog #: 21865-1-AP, Proteintech, 86 
Rosemont, IL). Anti-collagen IV (catalog #: ab135802) and anti-TATA binding protein (TBP) 87 
antibodies (catalog #: ab818) were purchased from from Abcam (Cambridge, MA). Antibodies against 88 
fibronectin (catalog #: F3648) and Orai1(catalog #: O8264) were from Sigma-Aldrich (St Louis, MO). 89 
Anti-GLP1R antibody (catalog #: 97308) was from Novus Biologicals (Littleton, CO). Anti-p65 90 
antibody (catalog #: 622601) was purchased from BioLegend (San Diego, CA). Anti-GAPDH antibody 91 
(catalog #: MAB374) was purchased from Millipore-Sigma (Burlington, MA) and anti-α-tubulin 92 
antibody was purchased from Santa Cruz Biotechnologies (Dallas, TX) (catalog #: sc-5286). Secondary 93 
antibodies for immunoblot, including goat anti mouse Ig horseradish peroxidase (catalog #: 31430) and 94 
goat anti rabbit Ig horseradish peroxidase (catalog #: 31460) were purchased from Invitrogen (Rockford, 95 
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IL). The secondary antibody used for immunohistochemistry (anti-rabbit poly- horseradish peroxidase 96 
IHC Reagent) was purchased from General Bioscience Corporation (catalog #: IHC-2291). 97 
Chemicals: Thapsigargin (TG) (catalog #: 586005), tunicamycin (catalog #: 504570), and 2,3-APB 98 
(catalog #: D9754) were purchased from Calbiochem-Millipore-Sigma. Helenaline (catalog #: 50-148-99 
9989) and exendin 9-39 (catalog #: AAJ66126EXD) were purchased from Fisher Scientific. GSK-100 
7975A was kindly donated by GlaxoSmithKline (Brentford, UK). Peroxidase substrate solution (DAB 101 
peroxidase substrate kit SK-4100) was purchased from Vector Laboratories (Burlingame, CA). 102 
Cell culture. Human MCs (HMCs) were purchased from Sciencell Research Laboratories (catalog #: 103 
4200, Carlsbad, CA). HMCs were cultured in a 75-cm2 flask with complete HMC media containing 104 
normal glucose (5.6 mM; NG) DMEM (GIBCO, Carlsbad, CA) supplemented with 25 mM HEPES, 4 105 
mM glutamine, 1.0 mM sodium pyruvate, 0.1 mM nonessential aminoacids, 100 U/ml penicillin, 100 106 
μg/ml streptomycin, and 15% fetal bovine serum (FBS). At ~80% confluence, the cells were split into 107 
60-mm culture plates or 12-well plates for various treatments as specified in figure legends. The cells 108 
were growth arrested using serum deprived media overnight. The culture media was replaced with fresh 109 
media at 2-day intervals. HMCs were used between subpassages 4 and 9 only. 110 
Human Proximal Tubular Epithelial Cells (HPTECs) were also purchased from Sciencell Research 111 
Laboratories (catalog #: 4100). HPTECs were cultured in complete EpiCM media (ScienCell Research 112 
laboratories) that was constituted by adding 5 ml Epi cell growth supplement, 10 ml FBS (2%) and 5 ml 113 
penicillin/streptomycin to the basal EpiCM media. Upon reaching ~80% confluence, the cells were split 114 
into 60-mm dishes for transfection experiments. The HPTECs were used between subpassages 4 and 9. 115 
Transient transfection of HMCs and HPTECs. To knock down the target proteins, HMCs were 116 
transiently transfected with siRNA against human Orai1 or human p65 or scramble control siRNA (50 117 
nM) using Dharmafect2 transfection reagent (Thermo Scientific, Rockford, IL) in serum free DMEM 118 
media following the protocol provided by the manufacturer. Media was changed to 15% FBS DMEM 119 
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media after 6 h.  Cells were harvested for Western blot 72 h after transfection. Human IL6/sIL6R 120 
expression plasmids (0.5 µg/ml) were transfected into HMCs and HPTECs was carried out using 121 
Lipofectamine LTX reagents (Invitrogen-BRL, Carlsbad, CA) in their respective serum free medias 122 
following the protocols provided by the manufacturer. Cells treated with transfection reagent alone 123 
served as the control. The media was changed with complete HMC media and complete EpiCM media 124 
after 6 h. Cells were collected 48 h after transfection for Western blot analysis.  125 
Enzyme-linked immunosorbent assay. Concentrations of IL6 in media were determined by a solid-126 
phase sandwich enzyme-linked immunosorbent assay using DuoSet ELISA Development kit for human 127 
IL6 (catalog #: DY206-05, R&D System, Minneapolis, MN) determined the abundance of IL6 in 128 
supernatant media. Briefly, HMCs were plated in 12-well plates as 5 X 104 cells per well. After attaining 129 
confluency, the cells were serum deprived till the end of experiment. The cells were treated with 1 µM 130 
TG (SOCE activator) in the presence or absence of 10 µM GSK-7975A (SOCE inhibitor) 15 h prior to 131 
sample collection. Supernatant media was collected 24 h later, centrifuged at 1500 rpm for 10 min at 132 
4°C and stored at -80°C until use. All samples were assayed using the protocol provided by the 133 
manufacturer. The optical density was determined at 450 nm in a microplate reader. The standard curve 134 
was obtained using the Sigma plot software version 11. 135 
Immunoblot Analysis. Immunoblots were performed as described in our previous publication (11). 136 
Briefly, the whole cell lysates or nuclear and cytosolic extracts were fractionated by 10% SDS-PAGE, 137 
transferred to PVDF membranes, and probed with primary antibodies. Bound antibodies were visualized 138 
with Super Signal West Femto or Pico Luminol/Enhancer Solution (catalog #: 34095 and 34087, 139 
Thermo Scientific, Rockford, IL). The specific protein bands were visualized and captured using the 140 
AlphaEase FC Imaging System (Alpha Innotech, San Leandro, CA). The integrated density value (IDV) 141 
of each target band was measured by circumscribing the band with a rectangle using AlphaEase FC 142 
software with autobackground subtraction. The amounts of target proteins, except nuclear proteins, were 143 
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quantified by normalization of their band IDVs to those of tubulin or GAPDH bands on the same blot.  144 
The contents of nuclear p65 proteins were normalized to TBP. 145 
Preparation of nuclear extracts. Preparation of nuclear extracts from HMCs was performed using NE-146 
PER nuclear and cytoplasmic extraction reagents (catalog #: 78833, Thermo Scientific, Rockford, IL) 147 
following the manufacturer’s protocol. The extracts were stored at -80⁰C until use. 148 
Animals. All procedures involving mice were approved by the University of North Texas Health 149 
Science Center (UNTHSC) Institutional Animal Care and Use Committee. Six male C57BL/6 mice were 150 
purchased from Charles River Laboratories (Wilmington, MA). All mice used in this study were 151 
between 2 and 4 months of age. The animals were maintained at the animal facility of UNTHSC 152 
vivarium in accord with local and National Institutes of Health guidelines. 153 
 In Vivo siRNA delivery into MCs of Mice. A targeted nanoparticle/siRNA in vivo delivery system 154 
was employed in mice to deliver siRNAs against mouse Orai1 (siOrai1) selectively into MCs. The 155 
compositions and features of the NPs, the formulation of the NPs with siRNA, and the protocols of in 156 
vivo delivery of the NPs/siRNA complex were described in our previous publications (10, 67, 68, 72). 157 
Mice were randomly divided into control and Orai1–knocked down groups (three mice in each group). 158 
The NPs containing siOrai1 (NP/siOrai1) were given through tail vein injection at a dose of 10 mg/kg 159 
siRNA in a volume of 100 µl to the mice in the Orai1–knocked down group. Mice in the control group 160 
were given NPs containing scramble siRNA (NP/scramble siRNA) through the same route with the 161 
same injection volume and dose. siRNA was injected on days 1 and 3 and the mice were euthanized on 162 
day 5. Mice were sacrificed by intraperitoneal injection of an overdose of anesthetic (100 mg/kg 163 
ketamine + 10 mg/kg xylazine), and then perfused with PBS to wash out the blood completely. After 164 
removal of the right kidney for biochemical assay, the mice were further perfused with 4% 165 
paraformaldehyde. The left kidney was then removed, fixed in 4% paraformaldehyde overnight, 166 
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dehydrated, embedded in paraffin and and cut into 4 µm-thickness sections (Cryostat 2800 Frigocut-E; 167 
Leica Instruments). 168 
Immunohistochemistry (IHC). After rehydration, kidney sections were immersed in 10 mM citrate 169 
buffer and heated to 60°C for 10 min to retrieve antigens. The sections were blocked by 5% goat serum 170 
for 30 min at room temperature and then were incubated with anti-GLP1R rabbit antibody at 1:200 in a 171 
humidified chamber overnight at 40C. The sections were incubated with anti-rabbit poly horseradish 172 
peroxidase IHC reagent at room temperature for 1 h, followed by incubation with peroxidase substrate 173 
solution. The slides were then dipped in hematoxylin solution for 30 seconds, dehydrated in an incubator 174 
at 600C for 30 min and cover-slipped with mounting media.  Sections were examined under an Olympus 175 
microscope (BX41) and an Olympus DP70 digital camera with DP manager software (version 2.2.1). 176 
Images were converted to 16-bit format and uniformly adjusted for brightness and contrast using ImageJ 177 
(version 1.50b; NIH). Semiquantification of the glomerular staining was conducted by a blinded 178 
observer using the ImageJ program following the instructions previously described (53). 179 
Statistical Analyses. Data are reported as mean ± SEM. Single-factor ANOVA plus Newman–Keuls 180 
post hoc analysis and unpaired t test were used to analyze the differences among multiple groups and 181 
between two groups, respectively, except as indicated in figure legends. P<0.05 was considered 182 
statistically significant. Statistical analyses were performed using SigmaStat (Jandel Scientific, San 183 
Rafael, CA). 184 
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RESULTS 186 
Overexpression of IL6 in HMCs suppressed ECM protein production by HMCs 187 
To determine the effect of IL6 on ECM protein production by HMCs, we transfected HMCs with 188 
expression plasmid pCDM8-H-IL-6 which expresses the fusion protein for IL6 and soluble IL6 receptor 189 
complex (IL6/sIL6R) (22). The IL6/sIL6R complex then associates with the gp130 unit on HMCs to 190 
activate the downstream IL6 trans-signaling pathways. Fibronectin band at the size of 220 kDa and 191 
collagen IV (Col IV) protein at the size of 160 kDa size were analyzed by immunoblot.  Overexpression 192 
of IL6/sIL6R in HMCs significantly decreased the protein abundance of fibronectin (Fig. 1 A and C) 193 
and Col IV (Fig. 1 B and D) as compared to the un-transfected cells and the cells transfected with 194 
transfection reagent only (a control). To further determine if this effect of IL6 was MC specific, we 195 
repeated the experiments in HPTECs. Contrary to the results in HMCs, overexpression of IL6/sIL6R 196 
(i.e. upregulating IL6 signaling) significantly increased fibronectin abundance in HPTECs (Fig. 1 E and 197 
F). Overexpression of IL6/sIL6R by transfection with pCDM8-H-IL-6 plasmids was verified by 198 
immunoblot (Fig. 1 G and H). These results suggest that IL6 effects in MCs are distinct from its effects 199 
in other kidney cell types, and that IL6 signaling in MCs is an inhibitory mechanism for ECM 200 
production.  201 
SOCE increased the secretion and production of IL6 in HMCs 202 
We have previously reported that SOCE suppressed production of ECM proteins including 203 
fibronectin and Col IV by MCs (68). To determine if IL6 signaling pathway mediated the SOCE effect, 204 
we examined the influence of SOCE manipulation on IL6 secretion and production by HMCs. IL6 205 
secretion was evaluated by measuring IL6 concentrations in the culture media of HMCs with or without 206 
TG (activation of SOCE) in the presence or absence of GSK-7975A (inhibition of SOCE). As compared 207 
to untreated control HMCs, TG treatment (1 µM for 15 h) significantly increased the secretion of IL6, 208 
and GSK-7975A (10 µM) abrogated the TG response (Fig. 2 A). 209 
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Similarly, Western blot analysis showed a significant increase in the abundance of IL6 protein in 210 
the cells treated with TG (1 µM for 15 h), which was also prevented by GSK-7975A (10 µM) (Fig. 2 B 211 
and C). Because TG is a known endoplasmic reticular (ER) stress inducer (30, 49), we carried out 212 
additional experiments to examine if ER stress contributed to the TG-induced response. To this end, 213 
HMCs were treated with tunicamycin, which induces the ER stress through a mechanism distinct from 214 
that of TG (26, 49, 71). As shown in Fig. 2 D and E, tunicamycin treatment (10 µM for 15 h) did not 215 
alter the abundance of IL6 in HMCs as compared to untreated cells, suggesting that the TG-induced 216 
increases of IL6 secretion and production by MCs were attributable to SOCE activation, but not the ER 217 
stress. Taken together, these results provide evidence that SOCE stimulates both secretion and 218 
production of IL6 by MCs.  219 
Knockdown of Orai1 decreased IL6 content in HMCs 220 
Orai1 protein is the pore-forming unit of the channel mediating SOCE (20, 51). If SOCE 221 
stimulated production of IL6 protein as shown above, silencing Orai1 and, thus, downregulating SOCE 222 
would be expected to reduce IL6 content. This speculation was tested by transfecting HMCs with siRNA 223 
against human Orai1. Indeed, IL6 content fell in HMCs transfected with Orai1 siRNA (Fig. 3). These 224 
data are consistent with the data presented above (Fig. 2) and further suggest a positive regulation of IL6 225 
production by SOCE in MCs. 226 
Inhibition of NFκB blunted SOCE-stimulated IL6 production in HMCs 227 
NFκB is a major transcription factor for many immune mediated processes.  We next examined 228 
if NFκB was involved in the SOCE-induced IL6 production. We suppressed NFκB signaling 229 
pharmacologically with helenaline (an NFκB activation inhibitor) and biologically by silencing p65 (a 230 
key component of NFκB) using the siRNA approach. As shown in Fig. 4 A and B, helenaline (1 µM) 231 
significantly blunted the TG-induced increase in IL6 protein abundance in HMCs. In agreement with 232 
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these results, p65 siRNA but not scrambled siRNA (control) completely abrogated the TG-induced 233 
increase in IL6 in HMCs (Fig. 4 C and D). 234 
SOCE stimulated nuclear translocation of NFκB 235 
After activation, NFκB is translocated to the nucleus to modulate the transcriptional activity of 236 
its target genes (3). If NFκB mediates SOCE-stimulated IL6 production, manipulation of SOCE should 237 
alter the nuclear translocation of NFκB. This speculation was tested by analyzing the dynamic 238 
distribution of NFκB p65 subunit in the cytosolic compartment and nucleus in response to SOCE 239 
activation. As shown in Fig. 5, TG treatment significantly increased p65 content in the nuclear fractions 240 
and this increase was significantly attenuated by 2-APB, an inhibitor of SOCE channel. However, the 241 
cytosolic extracts did not show any significant treatment effects on p65 content (Fig. 5). These results, 242 
combined with the results presented in Fig. 4, suggest that NFκB pathway mediated the SOCE-243 
stimulated IL6 production in HMCs. 244 
Glucagon-like peptide 1 (GLP-1) mediated IL6 suppression of ECM protein production in HMCs  245 
GLP-1 has multiple physiological actions including stimulation of insulin secretion and 246 
regulation of glucose metabolism (8).  GLP-1 is mainly produced by the intestinal L cells and its 247 
receptor (GLP-1R) is found on many target cell types including glomerular MCs (9, 39).  GLP-1R 248 
signaling was found to be protective in kidneys of diabetic animals (16). Recently we reported that GLP-249 
1R signaling suppressed ECM protein production in MCs (29).  To further explore the possibility that 250 
this novel renoprotective pathway mediated IL6 inhibition of ECM protein production by MCs, we 251 
conducted immunoblot analysis and examined GLP-1R contents in response to upregulation of IL6 252 
signaling. As shown in Fig. 6 A and B, overexpression of IL6/sIL6R by transfecting HMCs with 253 
pCDM8-H-IL-6 plasmids (upregulating IL6 signaling) significantly increased GLP-1R contents. To 254 
further interrogate the involvement of GLP-1R in IL6 signaling, we treated HMCs which had been 255 
transfected with pCDM8-H-IL-6 plasmids with exendin 9-39, a GLP-1R antagonist. Immunoblot 256 
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analysis was conducted to examine fibronectin protein abundance in response to the treatments. Same as 257 
the data presented in Fig. 1, overexpression of IL6/sIL6R again reduced fibronectin protein abundance. 258 
However, this effect was significantly blunted, albeit not completely abolished by inhibition of GLP-1R 259 
with exendin 9-39 (Fig. 6 C and D). These results suggest that GLP-1R signaling at least partially 260 
mediated the IL6-inhibited fibronectin production by HMCs. 261 
In vivo knockdown of Orai1 in MCs decreased glomerular GLP-1R content in mice.  262 
We have shown that SOCE promoted IL6 protein production (Figs. 2 and 3). We also showed 263 
that GLP-1R signaling was a downstream mediator of IL6 for its inhibition of fibronectin protein 264 
production (Fig. 6). To further confirm the SOCE/IL6/GLP-1R cascade in vitro, we next knocked down 265 
Orai1 in MCs in mice using the established targeted NP-siRNA delivery system (68, 72). Our previous 266 
studies have demonstrated that these NP/siRNA complexes were distributed predominantly in glomeruli 267 
with limited distribution in surrounding tubules (72). The NP/siOrai1 complexes used in that study 268 
highly colocalized with integrin-8 (MC marker) but were not colocalized with synaptopodin (marker for 269 
podocytes), suggesting that the NP/siRNA complexes were selectively delivered to MCs (10). Orai1 270 
silencing was verified by a marked decrease in Orai1 protein content in renal cortex of the mice treated 271 
with NP/siOrai1 (68). Using this established technique, we treated mice with either NP/scrambled 272 
siRNA (control) or NP/siOrai1 and examined GLP-1R content by immunohistochemistry in the kidney 273 
sections. In the mice treated with NP/scrambled siRNA, both glomeruli and tubules showed overt GLP-274 
1R staining (brown color). However, in the mice treated with NP/siOrai1, the glomerular GLP-1R 275 
staining was significantly reduced while the GLP-1R staining in the tubules changed very little (Fig. 7). 276 
These immunohistochemical data further support the proposed role of GLP-1R as a downstream effector 277 
of the SOCE pathway. 278 
  279 
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DISCUSSION 280 
The pathogenesis of CKDs is multifactorial. The role of activated immune processes and 281 
inflammation has been recently recognized in the development of CKDs including DN (41, 47, 62). A 282 
potent regulator of immune and inflammatory responses (48), IL6 also participates in cell growth and 283 
differentiation, hematopoiesis and metabolism. IL6 is a well-documented proinflammatory mediator in 284 
encephalitis, colitis, arthritis and other inflammatory disorders (23, 57, 69). On the other hand, IL6R 285 
blockade can exacerbate certain inflammatory conditions e.g. inflammatory eye disease, psoriasis, and in 286 
the kidney, crescentic immune complex glomerulonephritis (45, 65, 66).  Therefore, IL6 can play both 287 
pro-inflammatory and anti-inflammatory roles, although the molecular mechanisms for the double roles 288 
of IL6 are not clear. Specifically, the role of IL6 in renal inflammation needs to be delineated. Although 289 
data indicates its clear proinflammatory role in lupus nephritis, IL6 has been found to be protective in 290 
nephrotoxic nephritis (43). Lei et al. found that both classical and trans- signaling of IL6 in podocytes 291 
was detrimental in high glucose environment (37) while Kurvari et al. reported that IL6 from podocytes 292 
acted as an anti-inflammatory agent for the glomerular endothelial cells (35).  Clearly, the role of IL6 293 
varies in the same organ possibly depending on the specific pathological stimulus, the cells affected, the 294 
molecular signaling pathways activated and the interplays with other cytokines and immune factors.  295 
This study focused on the glomerular MCs since these cells not only produce various cytokines/ 296 
chemokines, but are also a major source of glomerular ECM proteins (1, 34, 44, 55, 60). Although IL6 297 
contributes to the function and growth of MCs in an autocrine fashion (12), IL6’s function and 298 
regulation in these cells are not well known. MCs do not have the membrane receptor for IL6 and 299 
depend on the soluble IL6 receptor (sIL6R) to activate IL6 signaling. In this study we genetically 300 
upregulated the IL6 signaling in MCs using pCDM8-H-IL-6 plasmids that overexpress the protein of 301 
human IL6 fused to the human sIL6R. This approach assures that there is no influence of any inhibitory 302 
factors that might be simultaneously secreted by the MCs that might hamper the signaling. The results 303 
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indicated that IL6 signaling negatively regulated fibronectin and Col IV production by MCs. This 304 
inhibitory effect of IL6 is cell type specific because overexpression of IL6/sIL6R increased fibronectin 305 
protein abundance in HPTECs. These distinct effects of IL6 in different type of kidney cells exemplify 306 
the specificity of IL6’s pro- vs. anti-inflammatory character. The finding that IL6 inhibition on ECM 307 
protein production by MCs suggest that IL6 signaling in MCs may be a renoprotective mechanism to 308 
counteract ECM expansion, a pathologic hallmark of many kidney diseases. 309 
 A new finding in this study is that SOCE stimulated IL6 protein production and secretion in 310 
MCs, and thus is assumed to upregulate IL6 signaling pathway. To our knowledge, this is the first time 311 
to report that IL6 signaling can be regulated by SOCE. As we discussed above, IL6 function is cell 312 
context dependent. From the present study, it is unclear if the SOCE/IL6 regulatory mechanism is MC 313 
specific or a general mechanism operating in multiple cell types. Another significance of this finding is 314 
that we identified a new downstream pathway of SOCE. The multifunctional SOCE involves arrays of 315 
signaling pathways (10, 40, 61, 67, 70). The present findings add IL6 to the roster of signaling pathways 316 
impacted by SOCE. Because SOCE is the major Ca2+ signaling pathway in immune cells (58, 64) and 317 
IL6 is an important proinflammatory/anti-inflammatory agent, our findings may contribute new insights 318 
on the pathogenesis of a broad spectrum of inflammatory diseases. 319 
We previously demonstrated that SOCE inhibited ECM protein production by MCs through 320 
inhibition of Smad1 and Smad3 pathways (10, 67, 68). The present study showed that IL6 reduced 321 
fibronectin and Col IV production and that SOCE upregulated IL6 pathway. Therefore, activation of IL6 322 
signaling may also be one of mechanism mediating SOCE inhibitory effects on ECM protein production 323 
in MCs. However, it is not clear whether these downstream pathways of SOCE are independent of one 324 
another (in parallel) or share a common pathway (in serial) from the present study. It would be 325 
interesting to further study whether these downstream pathways have a crosstalk in future. 326 
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It is interesting to note that GLP-1R signaling at least partially mediated IL6 suppression of 327 
ECM protein production. GLP-1 is secreted by the intestinal L cells and plays multiple physiological 328 
functions apart from insulin secretion and regulation of glucose metabolism (15, 18, 36, 59). GLP-1R 329 
agonists have recently been used for patients with type 2 diabetes to improve glycemic control (4, 21). 330 
GLP-1R is expressed in kidney cells, including MC (6, 9, 39, 56). Increased GLP-1R signaling in kidney 331 
of diabetic animals delayed the progression of DN and ameliorated renal inflammation and injury (16, 332 
24, 32, 50). In the present study, GLP-1R antagonist attenuated, but did not entirely reverse the 333 
inhibitory effect of IL6 on fibronectin production, suggesting that in addition to GLP-1R pathways, one 334 
or more additional mechanisms contributes to the IL6 effects. For instance, IL6 may directly inhibit the 335 
downstream molecules of the profibrotic pathways like TGFβ-signaling involving smad3, smad1 as 336 
reported by a study (31).   Alternatively, IL6 can suppress directly the fibrotic factors like connective 337 
tissue growth factor which has been demonstrated by several previous studies (25, 39, 63). Furthermore, 338 
IL6 may regulate the Janus kinase - signal transducer and activator of transcription (JAK-STAT) 339 
pathway. When this pathway is activated, STAT is phosphorylated and then translocated to the nucleus 340 
to promote the STAT dependent gene expression.  The matrix metalloproteinase (MMP) family of 341 
proteases like MMP-1, MMP-3, MMP-9 are known STAT target genes (5, 14). Via JAK-STAT 342 
signaling, IL6 could conceivably activate these matrix metalloproteinases via JAK-STAT pathway, 343 
leading to increased degradation of ECM proteins (14). Nevertheless, further study is needed to identify 344 
additional mechanisms mediating IL6 inhibition on ECM protein production by MCs. 345 
In summary, we identified a novel SOCE/NFкB/IL6/GLP-1R signaling pathway in MCs (Fig. 8). 346 
This pathway may protect against kidney diseases by inhibiting MC-derived ECM protein deposition. 347 
Because overproduction of ECM proteins and mesangial expansion are major features of many kidney 348 
diseases, the present findings may foster development of new treatments for patients with kidney 349 
diseases. 350 
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FIGURE LEGEND 555 
Figure 1. Effects of IL6 on ECM protein production in cultured HMCs and HPTECs.  556 
A and B: Representative immunoblot showing fibronectin (220 kDa band) and Col IV (160 kDa band) 557 
content, respectively in HMCs with and without overexpression of IL6/sIL6R.  HMCs were without 558 
transfection (UT), or treated with transfection reagents only (Reag, serving as control) or with pCDM8-559 
H-IL6 plasmid (pIL6). Cells were harvested 48 h after transfection. GAPDH was used as the loading 560 
control. L: protein ladder. C and D: Summary data from experiments presented in A and B with n=9 561 
and n=4 respectively. **p<0.01, vs UT and Reag. n’ indicates the number of independent experiments. 562 
E: Representative immunoblot showing fibronectin abundance in HPTECs with and without 563 
overexpression of IL6/sIL6R. Cells were treated as described for HMCs (A). α-tubulin was used as the 564 
loading control. F: Summary data from the experiment indicated in E. n=6. **p<0.01, vs UT and Reag. 565 
‘n’ indicates the number of independent experiments. G and H: Representative immunoblot showing 566 
expression of transfected IL6 (between 60-80 kDa) and endogenous IL6 bands (24 kDa) in HMCs and 567 
HPTECs with and without pCDM8-H-IL-6 expression plasmids, respectively. α-tubulin was used as the 568 
loading control.  UT: without transfection; Reag: treated with transfection reagents only; pIL6: 569 
transfected with pCDM8-H-IL6 plasmid. 570 
Figure 2. SOCE increased secretion and production of IL6 protein by HMCs.  571 
A: ELISA showing IL6 concentrations in HMC culture media. HMCs were growth arrested with serum 572 
free DMEM media overnight. One group had no treatment (NT) and the other two groups were treated 573 
with TG (1 μM) with or without GSK-7975A (10 μM) for 15 h. Supernatants of the culture media were 574 
collected at the end of treatment. *p <0.05. B: Representative immunoblot showing the effect of SOCE 575 
on IL6 protein content in cultured HMCs. Serum deprived HMCs had no treatment (NT) or treated with 576 
TG (1 μM) with or without GSK-7975A (10 μM) for 15 h. α-tubulin was used as the loading control. C: 577 
Summary data from the experiment indicated in B. *p <0.05, vs NT and TG+GSK. n=5, ‘n’ indicates the 578 
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number of independent experiments. D. Representative immunoblot showing the effect of tunicamycin 579 
on IL6 protein content in cultured HMCs. Serum deprived HMCs had no treatment (NT) or treated with 580 
DMSO (1 :1000) or tunicamycin (10 μM) for 15 h. α-tubulin was used as the loading control. E: 581 
Summary data from the experiment indicated in B. n=5, ‘n’ indicates the number of independent 582 
experiments. 583 
Figure 3. Knockdown of Orai1 decreased IL6 content in HMCs. 584 
A: Representative immunoblot, showing effect of knockdown of Orai1 on IL6 protein abundance in 585 
different groups of HMCs. HMCs were either un-transfection (UT) or transfected with scrambled (scr) 586 
or Orai1 siRNA (siOrai1). Cells were harvested 3 days after transfection. α-tubulin was used as the 587 
loading control. B:  Summary data from experiments presented in A.  *p<0.05, vs UT and scr, n=6, ‘n’ 588 
indicates the number of independent experiments.   589 
Figure 4. Downregulation of NFκB pathway attenuated SOCE-induced IL6 protein production in 590 
HMCs. 591 
A: Representative immunoblot, showing IL6 protein abundance in HMCs after pharmacological 592 
inhibition of NFκB. HMCs were with no treatment (NT) or with  TG (1 μM) in the presence or absence 593 
of helenaline (1 μM) for 15 h. α-tubulin was used as the loading control.  B: Summary data showing IL6 594 
protein abundance in different groups.  * p<0.05, vs NT and TG + helenaline. n=6, ‘n’ indicates the 595 
number of independent experiments. C: Representative immunoblot, showing the protein levels of IL6 596 
and p65 subunit of NFκB in HMCs in different groups. HMCs were without treatment (UT), treated with 597 
DMSO (1:1000), TG (1 μM), transfected with scrambled siRNA (Scr), scrambled siRNA with TG (Scr + 598 
TG), and p65 siRNA with TG (si-p65 + TG). DMSO and TG were added 15 h before harvesting. Cells 599 
were harvested 72 h after transfection. α-tubulin was used as the loading control. D: Summary data 600 
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showing IL6 protein abundance in different groups. **p<0.01, vs UT and DMSO; ## p<0.01, vs Scr and 601 
si-p65+TG. n=5, n’ indicates the number of independent experiments. 602 
Figure 5. SOCE increased NFκB nuclear translocation in HMCs. 603 
A: Representative immunoblot, showing p65 protein abundance in nuclear and cytosolic fractions of 604 
HMCs. HMCs were either no-treated (NT) or treated with DMSO (1:1000), and TG (1 μM) with or 605 
without 2-APB (50 μM) for 2 h. TBP was the loading control for the nuclear proteins and α-tubulin was 606 
used as the loading control for the cytosolic proteins. B: Summary data from the experiment indicated in 607 
A. *p<0.05, vs TG, **p<0.01, vs UT and DMSO for nuclear proteins. n=6, n’ indicates the number of 608 
independent experiments. 609 
Figure 6. GLP-1R pathway was involved in IL6 suppression of fibronectin production in HMCs.  610 
 A: Representative immunoblot, showing GLP-1R protein abundance in HMCs un-transfected (UT) or 611 
treated with transfection reagents only (Reag) or transfected with pCDM8-H-IL6 plasmid (pIL6).  Cells 612 
were harvested 48 h after transfection. α-Tubulin was used as the loading control. B: Summary data 613 
from experiments in A. *p<0.05, vs. UT and Reag. n= 6, ‘n’ indicates the number of independent 614 
experiments. C: Representative immunoblot, showing fibronectin and GLP-1R protein abundance in 615 
HMCs without transfection (UT), treated with transfection reagents only (Reag) and transfected with 616 
pCDM8-H-IL6 plasmid (pIL6) with or without addition of GLP-1R antagonist exendin 9-39 (Exn9-39, 1 617 
µM).  Exendin 9-39 was added 24 h after transfection. Cells were harvested 48 h after transfection. α-618 
Tubulin was used as the loading control. D: Summary data from experiments in C. *p<0.05, vs. pIL6 619 
and Reag, **p<0.01, vs. UT and Reag. n=6, ‘n’ indicates the number of independent experiments. 620 
Figure 7. In vivo knockdown of Orai1 in MCs decreased GLP-1R content in glomeruli in mice.  621 
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A: Representative images of immunohistochemical staining of GLP-1R in kidneys of mice treated with 622 
NP/scrambled siRNA or NP/siOrai1. GLP-1R staining is indicated by brown color while nuclei are blue. 623 
Arrows indicate glomeruli are indicated by arrows. Original magnification 200X. B: Enlarged images of 624 
the region indicated by the red-dashed boxes in panel A. C: integrated density (ID) of GLP-1R staining 625 
averaged from 3 NP/scrambled siRNA- and 3 NP/siOrai1-treated mice. The numbers in parentheses 626 
under each bar represent the number of glomeruli analyzed from 5 sections per kidney. *P< 0.05, 627 
compared with NP/scrambled siRNA. 628 
Figure 8. SOCE induced, IL6-GLP-1R mediated suppression of ECM deposition by MCs. 629 
Simplified summary diagram depicting the pathway mobilized by activation of L6 signaling by Orai1-630 
mediated SOCE in MCs and the effect of IL6 on ECM proteins. Blue arrows indicate promotion of the 631 
pathway; red arrow indicates inhibition of the pathway; red broken arrow indicates possible alternative 632 
mechanisms. 633 
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